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Abstract 
The use of cannabinoid receptor agonists is gaining a strong interest both in human and veterinary medicine. The 
potential use of cannabimimetic compounds in companion animals was reviewed in 2007 for their role in tissue 
inflammation and pain. A better knowledge of type-1 cannabinoid receptor (CB1R) expression on the target popula-
tion may help in risk management in order to prevent unwanted side effects. We used 30-days old canine embryos 
to describe the distribution of CB1R by means of immunohistochemistry with a commercially available antibody.
CB1R immunoreactivity was mainly epithelial and included most structures of central and peripheral nervous system, 
inner ear, olfactory epithelium and related structures, eye and thyroid. Further investigative research on the role of the 
endocannabinoid system in the developmental biology field is needed, however, we show that in the canine species 
we must consider pregnancy as risk condition for developmental abnormalities that may arise upon the use of CB1R 
receptor agonists.
Keywords: Cannabinoid receptor 1, Embryo, Dog, Immunohistochemistry
© 2015 Pirone et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Cannabinoid receptor 1 (CB1R) is a G-pro-
tein coupled receptor that mediates the effects of 
Δ9-tetrahydrocannabinol (Δ9THC), the most potent psy-
chotropic constituent of cannabis sativa (Xie et al. 2012; 
Razdan 1986). Since its discovery in 1990 (Matsuda et al. 
1990), a “peripheral” receptor was also characterised 
[i.e., type-2 cannabinoid receptor (CB2R)] (Munro et al. 
1993); CB1R and CB2R, together with a family of endog-
enous lipid ligands and the machinery for their biosyn-
thesis and metabolism, are part of the endocannabinoid 
system (Skaper and Di Marzo 2012).
The role of CB1R and endocannabinoid signalling has 
been extensively studied in the adult nervous system: 
N-arachidonoylethanolamide (AEA) and 2-arachidonoyl-
glycerol (2-AG) are the principal natural CB1R agonists 
able to mediate a retrograde synaptic signalling (Kano 
et al. 2009) causing inhibition of neurotransmitter release 
by presynaptic neurons (Elphick and Egertova 2001). 
Despite the ubiquitous expression of CB1R (Katona 
2009), autoradiographic analysis of the brain distribution 
of (3H)CP-55,940 (a potent Δ9THC developed by Pfizer 
Inc., Groton, CT USA) (Herkenham et al. 1991a, 1991b) 
together with immunocytochemical investigations using 
different antibodies showed the highest concentrations 
of cannabinoid binding sites in the basal ganglia and cer-
ebellum (Egertova et al. 1998; Egertova and Elphick 2000; 
Tsou et al. 1998; Pettit et al. 1998).
Recent research on the role played by the endocan-
nabinoid system in reproduction was mostly focused 
on gametogenesis (Grimaldi et al. 2013; El-Talatini et al. 
2009) and early events leading to the establishment of 
pregnancy (Melford et al. 2014): it is reported that high 
levels of CB1R ligands impair reproductive function 
causing retarded embryo development, fetal loss and 
pregnancy failure (Paria et  al. 2001; Maccarrone et  al. 
2002; Maccarrone 2009). Also, absence of mediators are 
known to adversely affect peri-implantation embryonic 
development as confirmed by studies in CB1R−/− mice 
(Wang et  al. 2004) sanctioning that the CB1R mediated 
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signalling is essential for regular embryo development 
with any deviation from physiological expression leading 
to adverse events.
Despite pregnant bitches are unlikely to be exposed 
to Δ9THC, it is possible that CB1R agonists will be used 
in the future as therapeutic options for treatment of dif-
ferent disorders (Smith et  al. 2010). The CB1R/CB2R 
receptor agonist, Δ9-tetrahydrocannabinol (Δ9-THC; 
dronabinol; Marinol) and its synthetic analogue, 
Nabilone (Cesamet), were approved over 25 years ago as 
medicines for suppressing nausea and vomiting produced 
by chemotherapy. Sativex, (GW pharmaceuticals), a drug 
containing both Δ9THC and cannabidiol was licensed in 
2010 in the UK and Canada for the treatment of spastic-
ity due to multiple sclerosis in humans and was recently 
approved in several other countries. Targeting the endo-
cannabinoid system with cannabinoid receptor agonists 
is yet under investigation for several possible additional 
therapeutic targets (Pertwee 2012).
The potential use of cannabimimetic compounds in 
companion animals was reviewed in 2007 for their role in 
tissue inflammation and pain (Re et al. 2007): palmidrol 
[(palmitoylethanolamide (PEA)], an AEA analogue, 
resulted in resolution of clinical signs in cats with eosino-
philic granuloma (Scarampella et  al. 2001). We recently 
reported CB1R expression in different cell types of nor-
mal canine skin (Campora et al. 2012) and increased lev-
els of PEA and other bioactive lipid mediators in canine 
atopic dermatitis thus supporting the hypothesis of a 
protective role of these compounds during this inflam-
matory process (Abramo et al. 2014).
Potential adverse events might be managed if a better 
understanding of CB1R anatomical pattern is known: for 
this reason, this study aims to describe the morphologi-
cal distribution of CB1R in canine embryos by means of 
immunohistochemistry.
Results
Immunoreactivity against CB1R was found in most epi-
thelial structures while the mesenchyme was always 
found to be devoid of staining (Fig.  1, top image). 
Strongly stained structures were found in the developing 
nervous system, sensory organs (primordia of eyes, inner 
ear related structures and olfactory nerves) and thyroid.
Nervous system
Numerous CB1R immunoreactive fibers were detected. 
Some ganglial structures showed cytoplasmic immuno-
reactivity. The forebrain showed a dense plexus of posi-
tive fibres which seemed to arise from the primordia of 
olfactory bulbs (Fig.  2a). Choroidal plexa also showed 
the presence of CB1R as cytoplasmic immunostain-
ing (Fig.  2b). Strong immunoreactivity was observed 
throughout the hindbrain in the section including pri-
mordia of medulla oblongata and of the pons. Two sets 
of fibres were anatomically visible: rostro-caudal fibres 
Fig. 1 Photomicrographs of the developing canine embryo. The image on top shows all the structures (low magnification) that are enlarged in 
a–d; a high magnification of the parasagittal area of the hindbrain where rostro-caudal fibres and transverse fibres are visible; b high magnification 
of the developing semi-circular canal (transverse section) where epithelial immunoreactivity is visible as cytoplasmic staining; c high magnifica-
tion of the cochlear ganglion showing cytoplasmic immunostaining of cell bodies; d high magnification of the outer layer of the optic cup (future 
pigmented layer of retina) showing cytoplasmic immunoreactivity. Scale bar is 500 µm in the top image and 20 µm in a–d
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and transverse fibres. While rostro-caudal fibres were 
covering the entire hindbrain (excluding the medullary 
raphe), transverse fibres were located in the parasagittal 
area. Fibres crossing the medullary raphe were also vis-
ible (Figs. 1a, 3a, b). The developing spinal cord showed 
CB1R immunoreactivity in its white matter and most of 
the nerve fibres visible in the embryo body were always 
stained (not shown).
Inner ear primordia
Both the lateral and posterior semi-circular canals, the 
endo-lymphatic sac and the vestibulocochlear nerve 
showed intense membrane immunoreactivity (Fig. 4a, b). 
The vestibulocochlear ganglion showed a more intense 
cytoplasmic staining in its cochlear portion, while the 
vestibular portion was almost devoid of staining (Fig. 4b, 
c). The trigeminal ganglion, adjacent to the cochlear one, 
showed a strong cytoplasmic staining as well (Fig. 4b, d).
Primordium of the eye
Immunoreactivity was observed as cytoplasmic labeling 
in both the surface epithelium and the mesothelial layer 
(region of future substantia propria) of cornea, and the 
cuboidal epithelium covering the anterior part of the lens 
(Fig. 5a). The inner (neural) layer of the optic cup (future 
nervous layer of retina) as well the outer layer (future pig-
ment layer of retina) showed CB1R immunostaining in 
cell cytoplasm (Fig. 5b). The developing optic nerve was 
strongly marked (Fig. 5b).
Primordia of the nasal cavities
The olfactory epithelium showed cytoplasmic immu-
noreactivity; the underlying mesenchyme was devoid 
of staining but showed intense immunoreactivity of 
Fig. 2 Photomicrographs of the developing central nervous system 
focusing at the olfactory bulbs (a) and choroidal plexa (b). a asterisks 
indicate positive fibres in the developing olfactory cortex; b arrows 
indicate cytoplasmic immunostaining of choroidal plexa epithelial 
cells. Scale bars are equal to 50 µm
Fig. 3 Photomicrographs of the developing central nervous 
system focusing at the hindbrain; a low magnification of primordia 
of medulla oblongata (pmo) and of the pons (pp); mr indicates 
medullary raphe; dashed lines enclose the parasagittal area where 
transversal immunoreactive fibres were observed (enlarged in b). 
b high magnification of the square represented in a to show both 
longitudinal and transversal positive fibres. Scale bars are equal to 
100 µm (a) and 50 µm (b)
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the abundantly represented olfactory nerve branches 
(Fig. 5c).
Thyroid
Strong immunoreactivity was observed in the thyroid 
primordium. Immunostaining was located in cell cyto-
plasm and membranes (Fig. 6).
Discussion
Here we report for the first time the immunohistochemi-
cal localization of CB1R in the developing canine embryo. 
In developing rat embryos, CB1R messenger RNA was 
found in some cells of the neural tube, in several struc-
tures of the central and peripheral nervous system, in 
the retina as well as in two endocrine organs, the thyroid 
gland and the adrenal gland (Buckley et  al. 1998). Our 
results on CB1R protein expression in canine embryos 
corroborate some of the above mentioned findings.
Firstly, we found several central and peripheral nerv-
ous system structures to express CB1R. Previous stud-
ies reported CB1R expression to be spatio-temporally 
subsequent to neuronal differentiation in the early chick 
embryo (Begbie et al. 2004); an analogue of Δ9THC was 
then reported to disrupt neural development in chick 
embryos (Psychoyos et  al. 2008). Independent studies 
concurrently reported that CB1R is required for normal 
neuronal differentiation, axonal growth and pathfinding 
during neural development (Watson et al. 2008; Berghuis 
et al. 2007). A recent study identified SCG10/stathmin-2, 
a microtubule-binding protein, as the first Δ9THC-
sensitive molecular effector modulating directional 
growth of corticofugal axons in the developing cerebrum 
(Tortoriello et al. 2014).
Then we focused on sensory organs, such as inner ear 
structures, the developing eye and the olfactory epi-
thelium. Several nervous and non-nervous structures 
resulted to express CB1R.
Although morphological studies on the role played by 
endocannabinoids in the auditory system are scarce, it is 
reported that CB1R mRNA is expressed in the cochlear 
ganglion of the chick (Stincic and Hyson 2011). This is 
in accordance with our immunohistochemical data that 
showed an analogous pattern of staining in the canine 
embryos.
We showed different structures in the developing eye 
of canine embryos expressing CB1R. In the same view, 
Fig. 4 Photomicrographs of the developing inner ear and associated/adjacent nervous structures. Empty arrowheads indicate semi-circular canals 
(a, b); Full arrowhead indicate the endo-lymphatic sac (a); Arrow indicates the saccular area (a, b); Asterisk indicates the vestibulocochlear nerve 
immunostained fibres (a, b). while the trigeminal (trig) and the cochlear (co) ganglia showed cytoplasmic labelling, the vestibular ganglion (vest) 
was negative to CB1R presence. c high magnification of the cochlear (co) ganglion; d high magnification of the trigeminal (trig) ganglion. Scale bars 
are equal to 100 µm in a, b and to 50 µm in c, d
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Buckley and colleagues found the embryonic rat retina to 
express CB1R receptor mRNA (Buckley et al. 1998). Fur-
ther works on the CB1R localization in the eye structures 
are available in adult rats and humans (Straiker et  al. 
1999; Yazulla et al. 1999). Taken together these data sug-
gest that the wide distribution CB1R in both the anterior 
eye and the retina of dogs (present study) and humans 
(Straiker et al. 1999) may account for an influence of the 
endocannabinoid system in several different physiologi-
cal functions of the vision.
With regard to the olfactory epithelium, some data are 
available in Xenopus laevis tadpoles (Czesnik et al. 2007). 
The mentioned paper shows localization of CB1R-like 
immunoreactivity on dendrites of olfactory receptor neu-
rons: our data show analogous findings since both the 
canine embryo olfactory epithelium and the underlying 
olfactory nerve branches resulted to express the protein.
As stated above, the same work of Buckley et al. showed 
the thyroid gland and the adrenal gland to express CB1R 
mRNA in the rat embryo (Buckley et al. 1998). Although 
we did not find CB1R expression in the developing adre-
nal glands of canine embryos, thyroid was amongst the 
major immunostained organs.
Depending on the examined structure, different cellu-
lar localization of CB1 were recorded: in particular, while 
the cytoplasmic compartment was always immunoreac-
tive, we found membrane distribution in the developing 
thyroid gland. To this regard our study does not allow for 
mechanistic hypotheses and, although CB1 spatial seg-
regation is likely to affect receptor activity, it is reported 
that also intracellular CB1 receptors are functional 
(Rozenfeld and Devi 2008).
Conclusions
Our work may serve as a basis for further investigative 
research on the role of the endocannabinoid system in 
the developmental biology field; also, we show that in 
the canine specie several developing structures express 
CB1R. This latter finding should be considered in the use 
of already available cannabinomimetic compounds. Fur-
ther investigations are needed to clarify the physiological 
role of CB1R during canine embryo development.
Methods
Animals
Six canine embryos obtained from two different mothers 
subjected to hysterectomy were used in the present study. 
Embryos were graded as 30-days-old based on their mor-
phology according to Miller’s Anatomy of the Dog (Evans 
Fig. 5 Photomicrographs of the developing eye (a, b) and nasal 
cavities. a CB1R labelling is visible in the epithelium comprising the 
capsule of the lens (asterisks), in the cell cytoplasm of the mesothelial 
layer of the cornea (mes) and in the surface epithelium of cornea 
(arrowheads); b CB1R immunoreactive fibres of the optic nerve (opt), 
the inner (inn) and outer (arrow) layer of the optic cup (future nervous 
and pigmented layer of retina) are shown; c CB1R reactivity is visible 
in the olfactory epithelium (olf) and in the olfactory nerve branches 
(full arrowheads). Scale bars are equal to 50 µm
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1993). Briefly, the entire pregnant uterus was removed 
during surgery and promptly immersed in 10 % buffered 
formalin solution. Embryos were dissected after 24 h and 
kept in fresh 10  % buffered formalin solution for 48  h. 
Embryos were thus processed for routine paraffin embed-
ding. Serial 5 µm transverse sections were obtained and 
stained for either morphological (routine Haematoxylin 
and Eosin staining) or immunohistochemical evaluation 
of CB1R distribution. Sections were selected in order to 
include primordia of all the organs present at this embry-
onic stage.
This research was carried out according to the inter-
national regulation on the use of animals for scientific 
purposes (Directive 2010/63/EU) and all experimental 
procedures were approved by the local ethical committee.
Immunohistochemical procedure
Immunohistochemistry was performed on serial sections 
using a rabbit polyclonal anti-Cannabinoid Receptor I 
antibody (1:50, abcam, ab23703); a synthetic peptide cor-
responding to C terminal amino acids 461-472 of Human 
Cannabinoid Receptor was used to raise the antibody 
Epitope retrieval was carried out at 120 ℃ in a pressure 
cooker for 5  min with a Tris/EDTA buffer pH 9.0. Sec-
tions were pretreated in 1 % H2O2 (in 0.1 M PBS, pH 7.4, 
10 min) to quench endogenous peroxidase activity, then 
rinsed with 0.05  % tween-20 detergent (in 0.1  M PBS, 
3 × 10 min.), and blocked with 5 % goat normal serum 
(s-1000, Vector) (in 0.1 M PBS, 1 h). Sections were incu-
bated overnight at 4 °C in a solution containing the rabbit 
anti-CB1R, 2 % goat normal serum, 0.05 % triton X-100 
(in 0.1 M PBS). Subsequently they were rinsed in 0.1 M 
PBS, (3  ×  10  min), followed by 1  h incubation with a 
biotinylated goat anti-rabbit immunoglobulin (BA-1000, 
Vector Labs, Burlingame, CA), diluted 1:300 in PBS. Sec-
tions were again rinsed in 0.1 M PBS, 3 × 10 min. After 
1 h incubation with the ABC complex (pk-7200, Vector, 
Burlingame, CA) followed by further washes in 0.1  M 
PBS, (3 x 10  min) staining was visualized by incubating 
the sections in diaminobenzidine (DAB) (sk-4105, Vector, 
Burlingame, CA) solution.
Although we had already tested the primary antibody 
specificity in the canine specie by incubation with the 
corresponding peptide (Campora et  al. 2012), substitu-
tion of either the primary antibody, or anti-rabbit IgG, 
or the ABC complex by PBS or non-immune serum was 
performed. Under these conditions the immunostaining 
was abolished.
The microphotographs were taken with a light micro-
scope (Leitz Diaplan, Wetzlar, Germany) connected to a 
PC via a Nikon digital system (Digital Sight DS-U1, NIS-
Elements BR-4.13.00 software).
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